Heart failure is a major health concern in the United States, contributing significantly to healthcare costs. It occurs when the heart struggles to meet the body’s needs, leading to symptoms like shortness of breath, fatigue, and fluid retention.
While heart failure often involves a weakened heart muscle, about half of patients experience a different type of heart failure where the heart’s pumping ability is normal, but its relaxation is impaired. This condition is often called “stiff heart” heart failure.
A recent study from the University of Vermont raises concerns about the widespread use of beta-blocker medications in patients with this type of heart failure. Beta-blockers are commonly prescribed to manage heart conditions, including abnormal heart rhythms, high blood pressure, and to protect the heart after a heart attack.
These medications reduce the stress on the heart and blood vessels and are lifesaving for patients with “weak heart” heart failure, where the heart’s pumping ability is reduced.
However, the benefits of beta-blockers in “stiff heart” heart failure are less clear. This condition, also known as heart failure with preserved ejection fraction (HFpEF), occurs when the heart becomes stiff and struggles to relax and fill with blood.
Unlike “weak heart” heart failure, there are few proven medical treatments for this type of heart failure, and doctors often prescribe medications based on assumptions rather than solid evidence.
The University of Vermont team analyzed data from the TOPCAT study, a large clinical trial funded by the National Institutes of Health. The trial included patients with “stiff heart” heart failure, and about 80% of participants were taking beta-blockers.
The researchers found that beta-blocker use in these patients was associated with a 74% higher risk of hospitalization for heart failure.
The study suggests that beta-blockers may not only fail to benefit patients with “stiff heart” heart failure but could also worsen their symptoms. In this condition, the heart already struggles to relax and fill with blood.
Beta-blockers appear to increase pressures inside the heart, potentially leading to fluid retention and shortness of breath—common symptoms of heart failure.
Despite their widespread use, beta-blockers have not been thoroughly studied in “stiff heart” heart failure. This gap in research highlights the need for caution when prescribing these medications to patients with this specific type of heart failure.
The findings suggest that treatments proven to work for one type of heart failure may not be appropriate for another, even if the symptoms appear similar.
For patients and caregivers, these findings emphasize the importance of discussing treatment options with healthcare providers and exploring whether the prescribed medications are supported by evidence for their specific condition.
Researchers hope that these results will encourage further studies to develop effective therapies for “stiff heart” heart failure, a condition that currently lacks targeted treatments.
The study, led by Dr. Timothy Plante, was published in JAMA Network Open. It serves as a reminder that heart failure is a complex condition requiring tailored approaches to care rather than one-size-fits-all solutions.
If you care about high blood pressure, please read studies that early time-restricted eating could help improve blood pressure, and coconut sugar could help reduce blood pressure and artery stiffness.
For more information about blood pressure, please see recent studies about added sugar in your diet linked to higher blood pressure, and results showing plant-based foods could benefit people with high blood pressure.
Copyright © 2025 Knowridge Science Report. All rights reserved.
